Geneweave Biosciences

GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. Roche acquired GeneWEAVE for $425 in August 2015, to strengthen offerings in microbiology diagnostics.

Client Website

The acquisition provided Roche with GeneWEAVE's Smarticles technology, an innovative class of molecular diagnostics that quickly identifies multidrug- resistant organisms (MDROs) and assesses antibiotic susceptibility directly from clinical samples, without the need for traditional enrichment, culture or sample preparation processes.